Is the new bivalent COVID-19 vaccine the booster we’ve been waiting for?

The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.

TBD Health Empowers FOLX & Wisp Patients with Next-Day STD/STI Testing & More

What You Should Know: TBD Health, a sexual healthcare provider revolutionizing the medical landscape through unparalleled digital and in-person clinical care, today announced its entry into

January 19, 2024

Lesbian, gay and bisexual women respond more positively to tobacco marketing

People who identify as lesbian, gay and bisexual – particularly women – respond more positively to tobacco marketing, are more inclined to smoke cigarettes daily

March 15, 2024

EMA gives thumbs-down to GSK’s multiple myeloma drug, PTC’s Duchenne candidate

Multiple myeloma drug Blenrep and Duchenne muscular dystrophy therapeutic Translarna did not make the European Medicines Agency’s cut for full marketing authorization, the agency announced

September 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.